-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, RinHiGfOANzqTSYuW8iBcS4HhsnKpSgcCBISJ56lmNlK3eN0vEPPCBKNvMWB0Ur7 Q7kYT6kOaI+cXlZOO9+SgQ== 0000950134-06-002608.txt : 20060213 0000950134-06-002608.hdr.sgml : 20060213 20060213125556 ACCESSION NUMBER: 0000950134-06-002608 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20060213 DATE AS OF CHANGE: 20060213 GROUP MEMBERS: ANSBERT GADICKE GROUP MEMBERS: LUKE EVNIN GROUP MEMBERS: MPM ASSET MANAGEMENT INVESTORS 2003 BVIII LLC GROUP MEMBERS: MPM BIOVENTURES III GMBH & CO BETEILIGUNGS KG GROUP MEMBERS: MPM BIOVENTURES III PARALLEL FUND LP GROUP MEMBERS: MPM BIOVENTURES III-QP LP SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: BARRIER THERAPEUTICS INC CENTRAL INDEX KEY: 0001173657 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 223828030 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-79875 FILM NUMBER: 06602092 BUSINESS ADDRESS: STREET 1: 600 COLLEGE ROAD EAST STREET 2: SUITE 3200 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 6099451200 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: MPM BIOVENTURES III LP CENTRAL INDEX KEY: 0001173408 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: THE JOHN HANCOCK TOWER STREET 2: 200 CLARENDON STREET, 5TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 617 425 9200 MAIL ADDRESS: STREET 1: THE JOHN HANCOCK TOWER STREET 2: 200 CLARENDON STREET, 5TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: MPM BIO VENTURES III LP DATE OF NAME CHANGE: 20020514 SC 13G/A 1 f17241sc13gza.htm AMENDMENT TO SCHEDULE 13G sc13gza
 

     
 
OMB APPROVAL
 
 
OMB Number: 3235-0145
 
 
Expires: February 28, 2006
 
 
Estimated average burden hours per response...11
 
 
 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. 1)*

BARRIER THERAPEUTICS, INC.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
06850R 10 8
(CUSIP Number)
December 31, 2005
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     o Rule 13d-1(b)

     o Rule 13d-1(c)

     þ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 
 


 

                     
CUSIP No.
 
06850R 10 8 

 

           
1   NAMES OF REPORTING PERSONS:
MPM BioVentures III, L.P.
   
  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY): 
   
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

  (a)   o
  (b)   þ
     
3   SEC USE ONLY:
   
   
     
4   CITIZENSHIP OR PLACE OF ORGANIZATION:
   
  Delaware
       
  5   SOLE VOTING POWER:
     
NUMBER OF   108,961
       
SHARES 6   SHARED VOTING POWER:
BENEFICIALLY    
OWNED BY   0
       
EACH 7   SOLE DISPOSITIVE POWER:
REPORTING    
PERSON   108,961
       
WITH: 8   SHARED DISPOSITIVE POWER:
     
    0
     
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
   
  108,961
     
10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):
   
  o
     
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):
   
  0.5%
     
12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):
   
  PN

Page 2 of 14


 

                     
CUSIP No.
 
06850R 10 8 

 

           
1   NAMES OF REPORTING PERSONS:
MPM BioVentures III-QP, L.P.
   
  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY): 
   
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

  (a)   o
  (b)   þ
     
3   SEC USE ONLY:
   
   
     
4   CITIZENSHIP OR PLACE OF ORGANIZATION:
   
  Delaware
       
  5   SOLE VOTING POWER:
     
NUMBER OF   1,620,553
       
SHARES 6   SHARED VOTING POWER:
BENEFICIALLY    
OWNED BY   0
       
EACH 7   SOLE DISPOSITIVE POWER:
REPORTING    
PERSON   1,620,553
       
WITH: 8   SHARED DISPOSITIVE POWER:
     
    0
     
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
   
  1,620,553
     
10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):
   
  o
     
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):
   
  6.7%
     
12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):
   
  PN

Page 3 of 14


 

                     
CUSIP No.
 
06850R 10 8 

 

           
1   NAMES OF REPORTING PERSONS:
MPM BioVentures III Parallel Fund, L.P.
   
  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY): 
   
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

  (a)   o
  (b)   þ
     
3   SEC USE ONLY:
   
   
     
4   CITIZENSHIP OR PLACE OF ORGANIZATION:
   
  Delaware
       
  5   SOLE VOTING POWER:
     
NUMBER OF   48,942
       
SHARES 6   SHARED VOTING POWER:
BENEFICIALLY    
OWNED BY   0
       
EACH 7   SOLE DISPOSITIVE POWER:
REPORTING    
PERSON   48,942
       
WITH: 8   SHARED DISPOSITIVE POWER:
     
    0
     
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
   
  48,942
     
10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):
   
  o
     
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):
   
  0.2%
     
12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):
   
  PN

Page 4 of 14


 

                     
CUSIP No.
 
06850R 10 8 

 

           
1   NAMES OF REPORTING PERSONS:
MPM BioVentures III GmbH & Co. Beteiligungs KG
   
  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY): 
   
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

  (a)   o
  (b)   þ
     
3   SEC USE ONLY:
   
   
     
4   CITIZENSHIP OR PLACE OF ORGANIZATION:
   
  Germany
       
  5   SOLE VOTING POWER:
     
NUMBER OF   136,957
       
SHARES 6   SHARED VOTING POWER:
BENEFICIALLY    
OWNED BY   0
       
EACH 7   SOLE DISPOSITIVE POWER:
REPORTING    
PERSON   136,957
       
WITH: 8   SHARED DISPOSITIVE POWER:
     
    0
     
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
   
  136,957
     
10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):
   
  o
     
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):
   
  0.6%
     
12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):
   
  PN

Page 5 of 14


 

                     
CUSIP No.
 
06850R 10 8 

 

           
1   NAMES OF REPORTING PERSONS:
MPM Asset Management Investors 2003 BVIII LLC
   
  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY): 
   
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

  (a)   o
  (b)   þ
     
3   SEC USE ONLY:
   
   
     
4   CITIZENSHIP OR PLACE OF ORGANIZATION:
   
  Delaware
       
  5   SOLE VOTING POWER:
     
NUMBER OF   31,375
       
SHARES 6   SHARED VOTING POWER:
BENEFICIALLY    
OWNED BY   0
       
EACH 7   SOLE DISPOSITIVE POWER:
REPORTING    
PERSON   31,375
       
WITH: 8   SHARED DISPOSITIVE POWER:
     
    0
     
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
   
  31,375
     
10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):
   
  o
     
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):
   
  0.1%
     
12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):
   
  OO

Page 6 of 14


 

                     
CUSIP No.
 
06850R 10 8 

 

           
1   NAMES OF REPORTING PERSONS:
Ansbert Gadicke
   
  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY): 
   
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

  (a)   o
  (b)   þ
     
3   SEC USE ONLY:
   
   
     
4   CITIZENSHIP OR PLACE OF ORGANIZATION:
   
  United States
       
  5   SOLE VOTING POWER:
     
NUMBER OF   0
       
SHARES 6   SHARED VOTING POWER:
BENEFICIALLY    
OWNED BY   1,946,788*
       
EACH 7   SOLE DISPOSITIVE POWER:
REPORTING    
PERSON   0
       
WITH: 8   SHARED DISPOSITIVE POWER:
     
    1,946,788*
     
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
   
  1,946,788*
     
10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):
   
  o
     
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):
   
  8.1%
     
12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):
   
  IN
* The shares are held as follows: 1,620,553 by MPM BioVentures III-QP, L.P. (“BV III QP”), 108,961 by MPM BioVentures III, L.P. (“BV III”), 31,375 by MPM Asset Management Investors 2003 BVIII LLC (“BV AM III”), 48,942 by MPM BioVentures III Parallel Fund, L.P. (“BV III PF”) and 136,957 by MPM BioVentures III GmbH & Co. Beteiligungs KG (“BV III KG”). MPM BioVentures III GP, L.P. (“BV III GP”) and MPM BioVentures III LLC (“BV III LLC”) are the direct and indirect general partners of BV III, BV III QP, BV III PF and BV III KG. The Reporting Person is a member of BV III LLC and BV AM III.

Page 7 of 14


 

                     
CUSIP No.
 
06850R 10 8 

 

           
1   NAMES OF REPORTING PERSONS:
Luke Evnin
   
  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY): 
   
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

  (a)   o
  (b)   þ
     
3   SEC USE ONLY:
   
   
     
4   CITIZENSHIP OR PLACE OF ORGANIZATION:
   
  United States
       
  5   SOLE VOTING POWER:
     
NUMBER OF   0
       
SHARES 6   SHARED VOTING POWER:
BENEFICIALLY    
OWNED BY   1,946,788*
       
EACH 7   SOLE DISPOSITIVE POWER:
REPORTING    
PERSON   0
       
WITH: 8   SHARED DISPOSITIVE POWER:
     
    1,946,788*
     
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
   
  1,946,788*
     
10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):
   
  o
     
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):
   
  8.1%
     
12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):
   
  IN
* The shares are held as follows: 1,620,553 by MPM BioVentures III-QP, L.P. (“BV III QP”), 108,961 by MPM BioVentures III, L.P. (“BV III”), 31,375 by MPM Asset Management Investors 2003 BVIII LLC (“BV AM III”), 48,942 by MPM BioVentures III Parallel Fund, L.P. (“BV III PF”) and 136,957 by MPM BioVentures III GmbH & Co. Beteiligungs KG (“BV III KG”). MPM BioVentures III GP, L.P. (“BV III GP”) and MPM BioVentures III LLC (“BV III LLC”) are the direct and indirect general partners of BV III, BV III QP, BV III PF and BV III KG. The Reporting Person is a member of BV III LLC and BV AM III.

Page 8 of 14


 

Item 1.    
  (a)   Name of Issuer
Barrier Therapeutics, Inc.
  (b)   Address of Issuer’s Principal Executive Offices
600 College Road East
Suite 3200
Princeton, NJ 08540
Item 2.    
   (a) Name of Person Filing
MPM BioVentures III, L.P.
MPM BioVentures III-QP, L.P.
MPM BioVentures III Parallel Fund, L.P.
MPM BioVentures III GmbH & Co. Beteiligungs KG
MPM Asset Management Investors 2003 BVIII LLC
Ansbert Gadicke
Luke Evnin
  (b)   Address of Principal Business Office or, if none, Residence
c/o MPM Capital L.P.
The John Hancock Tower
200 Clarendon Street, 54th Floor
Boston, MA 02116
  (c)   Citizenship
All entities were organized in Delaware, except MPM BioVentures III GmbH & Co. Parallel-Beteiligungs KG which was organized in Germany. The individuals are United States citizens.
  (d)   Title of Class of Securities
Common Stock
  (e)   CUSIP Number
06850R 10 8
Item 3.   If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
Not applicable

Page 9 of 14


 

Item 4.   Ownership
  (a)   Amount Beneficially Owned:
         
MPM BioVentures III, L.P.
    108,961  
MPM BioVentures III-QP, L.P.
    1,620,553  
MPM BioVentures III Parallel Fund, L.P.
    48,942  
MPM BioVentures III GmbH & Co. Beteiligungs KG
    136,957  
MPM Asset Management Investors 2003 BVIII LLC
    31,375  
Ansbert Gadicke
    1,946,788 *
Luke Evnin
    1,946,788 *
Percent of Class:
         
MPM BioVentures III, L.P.
    0.5 %
MPM BioVentures III-QP, L.P.
    6.7 %
MPM BioVentures III Parallel Fund, L.P.
    0.2 %
MPM BioVentures III GmbH & Co. Beteiligungs KG
    0.6 %
MPM Asset Management Investors 2003 BVIII LLC
    0.1 %
Ansbert Gadicke
    8.1 %
Luke Evnin
    8.1 %
  (b)   Number of shares as to which the person has:
  (i)   Sole power to vote or to direct the vote
         
MPM BioVentures III, L.P.
    108,961  
MPM BioVentures III-QP, L.P.
    1,620,553  
MPM BioVentures III Parallel Fund, L.P.
    48,942  
MPM BioVentures III GmbH & Co. Beteiligungs KG
    136,957  
MPM Asset Management Investors 2003 BVIII LLC
    31,375  
Ansbert Gadicke
    0  
Luke Evnin
    0  

Page 10 of 14


 

  (ii)   Shared power to vote or to direct the vote
         
MPM BioVentures III, L.P.
    0  
MPM BioVentures III-QP, L.P.
    0  
MPM BioVentures III Parallel Fund, L.P.
    0  
MPM BioVentures III GmbH & Co. Beteiligungs KG
    0  
MPM Asset Management Investors 2003 BVIII LLC
    0  
Ansbert Gadicke
    1,946,788 *
Luke Evnin
    1,946,788 *
  (iii)   Sole power to dispose or to direct the disposition of
         
MPM BioVentures III, L.P.
    108,961  
MPM BioVentures III-QP, L.P.
    1,620,553  
MPM BioVentures III Parallel Fund, L.P.
    48,942  
MPM BioVentures III GmbH & Co. Beteiligungs KG
    136,957  
MPM Asset Management Investors 2003 BVIII LLC
    31,375  
Ansbert Gadicke
    0  
Luke Evnin
    0  
  (iv)   Shared power to dispose or to direct the disposition of
         
MPM BioVentures III, L.P.
    0  
MPM BioVentures III-QP, L.P.
    0  
MPM BioVentures III Parallel Fund, L.P.
    0  
MPM BioVentures III GmbH & Co. Beteiligungs KG
    0  
MPM Asset Management Investors 2003 BVIII LLC
    0  
Ansbert Gadicke
    1,946,788 *
Luke Evnin
    1,946,788 *
 
*   The shares are held as follows: 1,620,553 by MPM BioVentures III-QP, L.P. (“BV III QP”), 108,961 by MPM BioVentures III, L.P. (“BV III”), 31,375 by MPM Asset Management Investors 2003 BVIII LLC (“BV AM III”), 48,942 by MPM BioVentures III Parallel Fund, L.P. (“BV III PF”) and 136,957 by MPM BioVentures III GmbH & Co. Beteiligungs KG (“BV III KG”). MPM BioVentures III GP, L.P. (“BV III GP”) and MPM BioVentures III LLC (“BV III LLC”) are the direct and indirect general partners of BV III, BV III QP, BV III PF and BV III KG. The Reporting Person is a member of BV III LLC and BV AM III.
Item 5.   Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.
Item 6.   Ownership of More than Five Percent on Behalf of Another Person
Not Applicable

Page 11 of 14


 

Item 7.   Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.
Not Applicable
Item 8.   Identification and Classification of Members of the Group
Not Applicable
Item 9.   Notice of Dissolution of a Group
Not Applicable
Item 10.   Certification
Not Applicable

Page 12 of 14


 

SIGNATURE
     After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    Dated: February 9, 2006
             
MPM BIOVENTURES III, L.P.   MPM BIOVENTURES III-QP, L.P.
 
           
By:
  MPM BioVentures III GP, L.P.,   By:   MPM BioVentures III GP, L.P.,
 
  its General Partner       its General Partner
 
           
By:
  MPM BioVentures III LLC,   By:   MPM BioVentures III LLC,
 
  its General Partner       its General Partner
 
           
By:
 
\s\ Luke Evnin
  By:  
\s\ Luke Evnin
 
           
 
  Name: Luke Evnin       Name: Luke Evnin
 
  Title: Series A Member       Title: Series A Member
 
           
 
           
MPM BIOVENTURES III PARALLEL FUND, L.P.   MPM BIOVENTURES III GMBH & CO. BETEILIGUNGS KG
 
           
By:
  MPM BioVentures III GP, L.P., its General Partner   By:   MPM BioVentures III GP, L.P., in its capacity as the Managing Limited Partner
 
           
By:
  MPM BioVentures III LLC,
its General Partner
  By:   MPM BioVentures III LLC,
its General Partner
 
           
By:
 
\s\ Luke Evnin
  By:  
\s\ Luke Evnin
 
           
 
  Name: Luke Evnin       Name: Luke Evnin
 
  Title: Series A Member       Title: Series A Member
 
           
 
           
MPM ASSET MANAGEMENT INVESTORS 2003 BVIII LLC        
 
           
By:
 
\s\ Luke Evnin
  By:  
\s\ Ansbert Gadicke
 
           
 
  Name: Luke Evnin       Name: Ansbert Gadicke
 
  Title: Manager        
 
           
 
           
By:
 
\s\ Luke Evnin
       
 
           
 
  Name: Luke Evnin        
Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

Page 13 of 14


 

EXHIBIT A
JOINT FILING AGREEMENT
     In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Barrier Therapeutics, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.
     In evidence whereof, the undersigned have caused this Agreement to be executed on their behalf this 9th day of February, 2005.
             
MPM BIOVENTURES III, L.P.   MPM BIOVENTURES III-QP, L.P.
 
           
By:
  MPM BioVentures III GP, L.P.,   By:   MPM BioVentures III GP, L.P.,
 
  its General Partner       its General Partner
 
           
By:
  MPM BioVentures III LLC,   By:   MPM BioVentures III LLC,
 
  its General Partner       its General Partner
 
           
By:
 
\s\ Luke Evnin
  By:  
\s\ Luke Evnin
 
           
 
  Name: Luke Evnin       Name: Luke Evnin
 
  Title: Series A Member       Title: Series A Member
 
           
MPM BIOVENTURES III PARALLEL FUND, L.P.   MPM BIOVENTURES III GMBH & CO. BETEILIGUNGS KG
By:
  MPM BioVentures III GP, L.P.,   By:   MPM BioVentures III GP, L.P.,
 
  its General Partner       in its capacity as the Managing Limited Partner
 
           
By:
  MPM BioVentures III LLC,   By:   MPM BioVentures III LLC,
 
  its General Partner       its General Partner
 
           
By:
 
\s\ Luke Evnin
  By:  
\s\ Luke Evnin
 
           
 
  Name: Luke Evnin       Name: Luke Evnin
 
  Title: Series A Member       Title: Series A Member
 
           
MPM ASSET MANAGEMENT INVESTORS 2003 BVIII LLC        
 
           
By:
 
\s\ Luke Evnin
  By:  
\s\ Ansbert Gadicke
 
           
 
  Name: Luke Evnin       Name: Ansbert Gadicke
 
  Title: Manager        
 
           
By:
 
\s\ Luke Evnin
       
 
           
 
  Name: Luke Evnin        

Page 14 of 14

-----END PRIVACY-ENHANCED MESSAGE-----